

1


hereinafter compound **1**, or a pharmaceutically-acceptable salt thereof.

The invention also provides a pharmaceutical composition comprising compound **1**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier.

In one aspect, the invention provides a method of treating an ocular disease in a mammal, the method comprising administering to the mammal compound **1**, or a pharmaceutical composition of the invention. In one aspect the ocular disease is selected from the group consisting of uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, retinal vein occlusion and atopic keratoconjunctivitis. In particular, the ocular disease is diabetic macular edema or uveitis.

In separate and distinct aspects, the invention also provides synthetic processes described herein, which are useful for preparing compound **1**.


In one aspect, there is provided a process for preparing a compound of formula **1**:




1

or a pharmaceutically-acceptable salt thereof, the process comprising:


(a) reacting a compound of formula **6**:



with a compound of formula **7-PG**:



- 5 wherein R^A is hydroxyl or a leaving group and PG is an amino-protecting group, to give compound **1-PG**:



- (b) deprotecting compound **1-PG**; and
- 10 (c) optionally preparing a pharmaceutically-acceptable salt
to provide a compound of formula **1**, or a pharmaceutically-acceptable salt thereof.

- The invention also provides compound **1**, or a pharmaceutically acceptable salt thereof, as described herein for use in medical therapy, as well as the use of the compound of the invention in the manufacture of a formulation or medicament for
- 15 treating ocular diseases.

In another aspect, there is provided compound as described herein, for use in the treatment of an ocular disease in a mammal.

In yet another aspect, there is provided a use of the compound as described herein, in the manufacture of a medicament for the treatment of an ocular disease in a mammal.

DETAILED DESCRIPTION OF THE INVENTION

Chemical structures are named herein according to IUPAC conventions as implemented in ChemDraw software (PerkinElmer, Inc., Cambridge, MA).

Furthermore, the imidazo portion of the tetrahydroimidazopyridine moiety in the
5 structure of the present compound exists in tautomeric forms. The compound could equivalently be represented as